
profit jump boost share still under-valued
share follow somewhat mix quarter
view result better fear deserv ralli result
posit commentari confer call benefit
higher expect gross profit margin vs estimate
lower vs estimate sg expens vs
estimate lower expect tax rate vs estimate
profit margin strong adj ebitda translat
ebitda margin up ep forecast
total revenu forecast co
re-affirmed revenu guidanc target adj
ep adj manag
team still need execut gain final fda approv gener advair
wixela inhub success launch product think share
remain heavili discount trade ev ebitda ratio
discount specialti pharma peer
myl american segment receiv product approv
date two-third attribut inject product call
manag highlight progress make launch
fulphila biosimilar rate neulasta
pegfilgrastim leukocyt growth factor boost white blood
cell focus market commun oncolog clinic
share pre-filled syring market believ mylan
price fulphila discount neulasta brand
market opportun estim sale fulphila could reach
finish debt cash balanc
debt-to-ebitda ratio long-term co plan reduc
debt leverag ratio co gener adj
oper cash first month year
alreadi gener adj
valuat maintain buy rate pt arriv
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
share follow somewhat mix quarter view result better
fear deserv ralli result posit commentari confer call benefit
higher expect gross profit margin vs estimate lower vs estimate
sg expens vs estimate lower expect tax rate vs estimate profit
margin strong adj ebitda translat ebitda margin
up ep forecast total revenu forecast co re-affirmed
revenu guidanc target adj ep adj
manag team still need execut gain final fda approv gener advair wixela inhub
success launch product think share remain heavili discount trade ev ebitda ratio
discount specialti pharma peer
up ep forecast total revenu forecast
re-affirmed revenu guidanc target adj ep adj
 first month year alreadi gener adj
call manag reiter view expect receiv fda approv gener version advair
final label discuss believ advair fluticasone/salmeterol treatment asthma/copd
brand market opportun us remain key gener product opportun expect fda
approv decis co gener version late approv think could co
market offer gener bioequival version year product market
tradenam wixela inhub gsk gsk rate advair still one largest sell brand inhal product
us
report revenu vs estimate adj ep vs estimate
mylan key american segment experienc yoy drop net sale vs estimate
adj segment profit drop exclud morgantown restructur expens
 incom statement financi project cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
